Baloxavir Marboxil投与後に発症した血栓炎の症例
1Department of Endoscopy, Tanaka Clinic, Japan.
Internal medicine (Tokyo, Japan)
|September 3, 2025
まとめ
インフルエンザAの治療薬であるバロキサビルの使用は,大腸炎を引き起こす可能性があります. ある症例研究では 患者が薬剤を服用した後に大腸炎の症状を発症し,潜在的な有害事象が浮き彫りにされた.
科学分野:
- 胃腸内科
- 感染症
- 薬理学について
背景:
- インフルエンザAは一般的な呼吸器疾患です.
- バロキサビルは,インフルエンザAの治療に使用される抗ウイルス薬です.
- 薬の副作用はどんな薬でも起こり得る.
研究 の 目的:
- バルオクサビールマーボキシルと関連している可能性のある 血性大腸炎の症例を報告する
- 臨床医の意識を高めるために
主な方法:
- インフルエンザAでバロキサビルマーボキシルで治療を受けた60代の女性の症例報告
- 臨床的表現,大腸内視鏡検査の結果,および組織病理学的検査は文書化されました.
- 患者の管理と結果が記録された.
主要な成果:
- 腹痛,下痢,血栓症がバロキサビル投与後2日後に発症しました.
- コロノスコーピーはシグモイド結腸粘膜腫と縦断性潰瘍を明らかにした.
- 血液病理学では 結腸炎が確認されました
- 症状は保守的な治療で改善した.
結論:
- 発血性大腸炎は,バロキサビルマーボキシルに関連した潜在的な副作用です.
- 臨床医は,薬を服用した後に胃腸の症状が現れた患者の場合,この可能性を考慮する必要があります.
関連する概念動画
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Inflammatory Bowel Disease I: Ulcerative Colitis
316
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
316
Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
Inflammatory Bowel Disease IV: Pharmacological Management
185
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
185
Chronic Bowel Disorders: Introduction
540
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
540
Drugs for Treatment of Constipation-Predominant IBS
326
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
326


